secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K/A
Filed at:   2024-01-19T23:59:59+00:00
Accession:  0001104659-24-005246
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools completes SomaLogic acquisition; provides audited FY2022 and unaudited 9M2023 financials
--------------------------------------------------------------------------------

- Acquisition closed Jan. 5, 2024; SomaLogic becomes wholly owned subsidiary of Standard BioTools.
- SomaLogic FY2022 revenue $97.7M, net loss $109.2M; FY2021 revenue $81.6M, net loss $87.5M.
- Pro forma unaudited combined financials filed for FY2022 and 9M2023 reflecting the acquisition.
- SomaLogic had $421.8M cash and equivalents and $647.4M total assets at Dec. 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000110465924005246/0001104659-24-005246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000110465924005246/tm243472d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-005246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer